Updated Guidelines Broaden Eligibility for Cholesterol-Lowering Therapy

New hyperlipidemia guidelines from the AHA and ACC, replacing the PCE with PREVENT-ASCVD equations, significantly expand eligibility for cholesterol-lowering therapy. Now, 54.6% of adults aged 20–79 without established cardiovascular disease qualify, up from 41.3%. The updated recommendations lower risk thresholds and include chronic kidney disease and HIV as standalone qualifying conditions, impacting millions of adults.